PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28410959-7	2017	In the clinic, PMC s of treated patients showed upregulation of mRNA expression and protein levels of BDNF, CREB and AKT after addition of fluvoxamine.	Fluvoxamine	139-150	brain derived neurotrophic factor	Homo sapiens	102-106	
28410959-3	2017	The effect of fluvoxamine augmentation on BDNF-CREB pathways in peripheral mononuclear cells (PMC s) of medicated schizophrenia patients was also studied.	Fluvoxamine	14-25	brain derived neurotrophic factor	Homo sapiens	42-46	
21179660-7	2010	In addition, responders to fluvoxamine, paroxetine, milnacipran, and sertraline all increased serum BDNF levels.	Fluvoxamine	27-38	brain derived neurotrophic factor	Homo sapiens	100-104	
25756551-2	2015	Recent evidence from animal and clinical studies that adding fluvoxamine to antipsychotics alters the expression of transcripts encoding for the GABA-A receptor and BDNF led us to postulate that fluvoxamine augmentation may improve memory in schizophrenia.	Fluvoxamine	61-72	brain derived neurotrophic factor	Homo sapiens	165-169	
25756551-2	2015	Recent evidence from animal and clinical studies that adding fluvoxamine to antipsychotics alters the expression of transcripts encoding for the GABA-A receptor and BDNF led us to postulate that fluvoxamine augmentation may improve memory in schizophrenia.	Fluvoxamine	195-206	brain derived neurotrophic factor	Homo sapiens	165-169	
25089150-1	2014	BACKGROUND: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.	Fluvoxamine	140-151	brain derived neurotrophic factor	Homo sapiens	82-115	
25089150-1	2014	BACKGROUND: We investigated the association between serum proBDNF, a precursor of brain-derived neurotrophic factor (BDNF), and response to fluvoxamine in patients with major depressive disorder (MDD) using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR): physically healthy and free of current alcohol or drug abuse, comorbid anxiety, or personality disorders.	Fluvoxamine	140-151	brain derived neurotrophic factor	Homo sapiens	61-65	
17092970-0	2007	The G196A polymorphism of the brain-derived neurotrophic factor gene and the antidepressant effect of milnacipran and fluvoxamine.	Fluvoxamine	118-129	brain derived neurotrophic factor	Homo sapiens	30-63	
17092970-2	2007	The purpose of the present study was to investigate whether the G196A polymorphism of the brain-derived neurotrophic factor (BDNF) gene is associated with the antidepressant effect of milnacipran, a serotonin norepinephrine reuptake inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor.	Fluvoxamine	248-259	brain derived neurotrophic factor	Homo sapiens	90-123	
17092970-2	2007	The purpose of the present study was to investigate whether the G196A polymorphism of the brain-derived neurotrophic factor (BDNF) gene is associated with the antidepressant effect of milnacipran, a serotonin norepinephrine reuptake inhibitor, and fluvoxamine, a selective serotonin reuptake inhibitor.	Fluvoxamine	248-259	brain derived neurotrophic factor	Homo sapiens	125-129	
17092970-7	2007	In all subjects receiving milnacipran or fluvoxamine, the G/A genotype of the BDNF G196A polymorphism was associated with a significantly better therapeutic effect in the MADRS scores during this study.	Fluvoxamine	41-52	brain derived neurotrophic factor	Homo sapiens	78-82	
17092970-9	2007	These results suggest that the BDNF G196A polymorphism in part determines the antidepressant effect of both milnacipran and fluvoxamine.	Fluvoxamine	124-135	brain derived neurotrophic factor	Homo sapiens	31-35	
16522641-12	2006	We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+]i) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release.	Fluvoxamine	163-174	brain derived neurotrophic factor	Homo sapiens	18-22	
16522641-12	2006	We found that the BDNF-stimulated PLC-gamma activation and the ensued increase in intracellular Ca2+ ([Ca2+]i) were potentiated by pretreatment with imipramine or fluvoxamine, so was the BDNF-induced glutamate release.	Fluvoxamine	163-174	brain derived neurotrophic factor	Homo sapiens	187-191	
31180700-0	2020	BDNF association study with obsessive-compulsive disorder, its clinical characteristics, and response to fluvoxamine-treatment in Iranian patients.	Fluvoxamine	105-116	brain derived neurotrophic factor	Homo sapiens	0-4